Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:26:11 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:KTTA from 2023-05-04 to 2024-05-03 - 22 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-29 07:59U:KTTANews ReleasePasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
2024-04-24 07:59U:KTTANews ReleasePasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
2024-02-13 07:59U:KTTANews ReleasePasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
2024-01-08 07:59U:KTTANews ReleasePasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
2024-01-02 08:35U:KTTANews ReleasePasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
2023-12-28 17:00U:KTTANews ReleasePasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
2023-12-19 17:19U:KTTANews ReleasePasithea Therapeutics Announces Results from 2023 Annual Meeting
2023-12-11 08:01U:KTTANews ReleasePasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
2023-11-29 16:27U:KTTANews ReleasePasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
2023-11-29 07:59U:KTTANews ReleasePasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
2023-11-09 07:59U:KTTANews ReleasePasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets Ž ±5 Ž ²1 Integrin for the Treatment of both Sporadic and Familial ALS
2023-09-14 08:30U:KTTANews ReleasePasithea Therapeutics Corp. Announces Final Results of Tender Offer
2023-09-07 16:14U:KTTANews ReleasePasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
2023-08-01 07:59U:KTTANews ReleasePasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in Ž ±5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting Ž ±5 integrin results in improved
2023-07-20 08:43U:KTTANews ReleasePasithea Therapeutics Announces Intention to Commence a $4.0 ‚  Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
2023-07-20 08:40U:KTTANews ReleasePasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
2023-06-30 09:28U:KTTANews ReleasePasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
2023-06-29 14:50U:KTTANews ReleaseLucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp.
2023-06-29 08:29U:KTTANews ReleasePasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
2023-06-06 16:30U:KTTANews ReleasePasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.
2023-06-05 09:00U:KTTANews ReleaseLucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.
2023-06-01 07:57U:KTTANews ReleasePasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference